NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Odyssey Therapeutics ODTX

Odyssey Therapeutics listed on Nasdaq on 8 May 2026 and is not in the S&P 500. It is worth $882 million. Its price history starts on 8 May 2026. 11 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 10.8% of the company.

CEO
Gary D. Glick
Listed
8 May 2026 on Nasdaq, IPO filings and terms
Headquarters
Boston, MA
Market cap
$882M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2025, from Odyssey Therapeutics' quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2025

Not reported for enough quarters.

Odyssey Therapeutics' market cap since May 2026

Weekly, up to 13 Nov 2026

Jun 2026JulAugSepOctNov$920M

Board and leadership

Board and officers

2 people here also hold roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (11)
Gary D. GlickPresident and Chief Executive OfficerPresident and Chief Executive Officer
Shelley ChuDirectorDirector
Paulina HillDirectorDirector
Jeffrey M. LeidenDirectorAlso at Vertex PharmaceuticalsDirector
Nan (ln) LiDirectorDirector
Carolyn NgDirectorDirector
Valerie OdegardDirectorDirector
Aranicki Ksenija PavleticDirectorDirector
Ian F. SmithDirectorDirector
Ourania TatsisDirectorAlso at Vertex PharmaceuticalsDirector
Timothy P. WalbertDirectorDirector
Officers (5)
Jason HaasChief Financial OfficerLast filed 11 May 2026Chief Financial Officer
Natalie DalesChief of Research Operations and Portfolio StrategyLast filed 11 May 2026Chief of Research Operations and Portfolio Strategy
Anthony W. OpipariInterim Chief Medical Officer and Executive Vice President, Translational MedicineLast filed 11 May 2026Interim Chief Medical Officer and Executive Vice President, Translational Medicine
Jolie SiegelExecutive Vice President, General Counsel and SecretaryLast filed 7 May 2026Executive Vice President, General Counsel and Secretary
Collin M. ToddSenior Vice President, Strategy and Business DevelopmentLast filed 11 May 2026Senior Vice President, Strategy and Business Development

Owners and trading

Largest institutional holders

Each fund group's share of Odyssey Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Fidelity (FMR)10.8%
  • Sr One Capital Management7.9%
  • Tpg GP A7.7%
  • Lightspeed Management Company, L.L.C.7.5%
  • Orbimed Advisors6.3%

These five hold 40.1% of Odyssey Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $20.3 million in 4 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
11 May 2026BuyNan (ln) LiDirectorDirectorBuy1,111,111$20M
11 May 2026BuyShelley ChuDirectorDirectorBuy11,111$200K
8 May 2026BuyJeffrey M. LeidenDirectorDirectorBuy5,000$100K
8 May 2026BuyJason HaasChief Financial OfficerChief Financial OfficerBuy1,000$20K

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no director or officer changes, WARN notices or large insider sales in the last two years.